Immune evasion mechanisms and immune checkpoint inhibition in advanced merkel cell carcinoma.

Schadendorf, Dirk; Nghiem, Paul; Bhatia, Shailender; Hauschild, Axel; Saiag, Philippe; Mahnke, Lisa; Hariharan, Subramanian; Kaufman, Howard L

Schadendorf, Dirk; Nghiem, Paul; Bhatia, Shailender; Hauschild, Axel; Saiag, Philippe; Mahnke, Lisa; Hariharan, Subramanian; Kaufman, Howard L.

Afiliação

Schadendorf D; Department of Dermatology, Essen University Hospital, Germany and German Cancer Consortium Partner Site Essen/Düsseldorf, Essen, Germany.
Nghiem P; Department of Medicine, University of Washington Medical Center, Seattle, WA, USA.
Bhatia S; Department of Medicine, University of Washington Medical Center, Seattle, WA, USA.
Hauschild A; Department of Dermatology, University of Kiel, Kiel, Germany.
Saiag P; Head of Service de Dermatologie Générale et Oncologique, University of Versailles-SQY, CHU A Paré, Boulogne Cedex, France.
Mahnke L; EMD Serono, Inc., Billerica, Boston, MA, USA.
Hariharan S; Pfizer Inc, New York, NY, USA.
Kaufman HL; Department of Surgery and Medicine, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.

Oncoimmunology ; 6(10): e1338237, 2017.

Article em En | MEDLINE | ID: mdl-29123950

Palavras-chave

Avelumab; Merkel cell carcinoma; PD-1; PD-L1; checkpoint inhibition; immune evasion; pembrolizumab

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Oncoimmunology Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Alemanha País de publicação: Estados Unidos

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google